Gujarat Themis Biosyn Investor Presentation June 2026

Subject to regulatory approvals
Purchase price: JPY 9.5 Billion (approximately ₹561.82 Crores based on INR/JPY rate of 0.59)
Target company FY26 Revenue: JPY 9.5 Bn (₹561.82 Crs)
60+ years of experience with 3 GMP-compliant plants having FDA & PMDA approval track record
Strategic rationale: Accelerates GTBL's transition towards fermentation-based globally integrated CDMO
Capabilities include: Microbial fermentation, plasmid DNA, ADC conjugation, P450 enzyme library, peptide production, enzyme engineering
Product portfolio: Fermentation-based immunosuppressants, oncology APIs, anti-infectives (Josamycin)
Customer relationships: Average business relationship of over 25 years with top 5 customers

Subject to regulatory approvals
Portfolio: Comprehensive mature brands for tuberculosis treatment and other infections
CY25 net sales: €62 million
Geographic distribution: Middle East & Africa (34.24% of sales), Europe (27.23% of sales)
Transaction structure: Asset deal including marketing authorization, brands, regulatory documentation, relevant contracts, and inventory
No transfer of manufacturing facilities or employees
Strategic rationale: Immediate geographical expansion to 59 countries, strong presence in Europe & MEA, entry into regulated markets
Portfolio includes WHO 2025 Essential Medicines, EU 2024 Critical Medicines, Drugs of Major Therapeutic Interest, French 2024 Essential Drugs

| Particulars | FY24 | FY25 | FY26 |

| Revenue from operations (net) | 16,982.19 | 15,079.99 | 16,582.28 |

| Other income | 436.57 | 243.24 | 242.81 |

| Total Income | 17,418.76 | 15,323.23 | 16,825.09 |

| Profit before tax | 7,933.43 | 6,553.79 | 6,209.00 |

| Current tax | 1,950.90 | 1,669.62 | 1,078.63 |

| Deferred tax | 37.51 | 28.05 | 462.23 |

| Profit after Tax | 5,916.32 | 4,877.17 | 4,668.15 |

| Particulars | FY24 | FY25 | FY26 |

| Total Assets | 22,111.33 | 30,131.25 | 50,342.66 |

| Equity Share Capital | 726.44 | 1,089.65 | 1,089.65 |

| Total Equity | 20,137.60 | 24,838.20 | 28,776.78 |

| Borrowings (Non-current) | - | 2,963.60 | 12,806.37 |

| Trade Receivables | 2,702.55 | 3,123.82 | 6,091.66 |

| Inventories | 332.68 | 504.61 | 1,542.27 |

| Cash and Cash Equivalents | 646.92 | 1,169.39 | 312.15 |

| Particulars | FY24 | FY25 | FY26 |

| Net cash from operating activities | 6,421.31 | 9,102.86 | 4,877.73 |

| Payments for property, plant and equipment | (7,464.46) | (11,615.02) | (17,253.44) |

| Proceeds from Borrowings (Net) | - | 2,988.99 | 12,997.55 |

| Dividend paid | (690.11) | (181.67) | (730.07) |